Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung
Authors:
- 29 January 2019
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 15 (5) , E126-E131
Abstract
Purpose: Lung cancer with malignant peritoneal carcinomatosis and malignant ascites is rare, often indicates the terminal stage, and is refractory to treatment. The median survival time of lung cancer patients with malignant ascites has been reported to be as short as 15 days to 2 months in retrospective studies.Methods: We reviewed all lung cancer patients who had cytologically or pathologically proven malignant ascites and received aggressive therapy including chemotherapy, anti‐angiogenesis agents and target therapy at a Taiwan hospital from January 2015 to December 2017. In addition, we searched PubMed using the terms “lung cancer,” “peritoneal carcinomatosis” and “malignant ascites” to find other studies reporting experience of such treatment.Results: Three consecutive lung cancer patients with malignant ascites (3/265, 1.13%) were included in this case series study, all of whom received bevacizumab with three other drugs (erlotinib, afatinib and gemcitabine). All of the patients showed a good response to treatment with a marked decrease in ascites. Two of the patients had a long progression‐free survival time of more than 5 months. In the literature review, several cases reports and case series documented the treatment efficacy, however no prospective or retrospective studies reported treatment strategies.Conclusions: Aggressive treatment for lung cancer with malignant ascites is encouraged when possible. Bevacizumab‐based treatment may serve as one effective treatment strategy for non‐squamous cell lung carcinoma with malignant ascites. Further prospective trials are urgently needed.Keywords
This publication has 17 references indexed in Scilit:
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyThe Lancet Oncology, 2014
- Lung cancer and peritoneal carcinomatosisOncology Letters, 2013
- Bevacizumab: overview of the literatureExpert Review of Anticancer Therapy, 2012
- Peritoneal carcinomatosis in lung cancerRespirology, 2008
- Gastro-intestinal metastasis of primary lung carcinoma: Clinical presentations and outcomeLung Cancer, 2006
- The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecologic Oncology, 2006
- Malignant ascites: Systematic review and guideline for treatmentEuropean Journal of Cancer, 2006
- Malignant ascites: past, present, and futureJournal of the American College of Surgeons, 2004
- Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion FormationThe Oncologist, 2000
- Role of Vascular Endothelial Growth Factor in Ovarian CancerThe American Journal of Pathology, 1998